Firsekibart Shown Safe in Phase 1 Study
In a groundbreaking Phase 1 clinical trial conducted in China, researchers have investigated Firsekibart, a novel anti-interleukin-1β monoclonal antibody, through a randomized, double-blind, placebo-controlled framework....